**#8103** 

# SignalSlide<sup>®</sup> Phospho-p44/42 MAPK (Thr202/Tyr204) IHC Controls

1 Pack (5 slides)

rev. 10/17/19

# For Research Use Only. Not For Use In Diagnostic Procedures.



Immunohistochemical analysis of paraffin-embedded NIH/3T3 cells, treated with U0126 #9903 (left) or TPA (12-0-Tetradecanoy/phorbol-13-Acetate) #4174 (right), using Phospho-p44/42MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP™ Rabbit mAb #4370.

**Description:** Each control slide contains formalin fixed, paraffin-embedded NIH/3T3 cells, treated with either U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene) #9903 or TPA (12-O-Tetradecanoylphorbol-13-Acetate) #4174, that serve as a control for phosphop44/42 MAPK (Thr202/Tyr204) immunostaining. U0126 has been shown to be a highly selective inhibitor of MEK1 and MEK2. TPA induces phosphorylation of p44/42 MAPK. Western blot analysis was performed on extracts derived from the same cells to verify the efficacy of the U0126 and TPA treatments.

Background: Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines (1-3) and is an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family as well as Mos and Tpl2/Cot. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors such as U0126 and PD98059.

**Applications:** These slides are intended for use in immunohistochemical assays.

## Background References:

- (1) Roux, P.P. and Blenis, J. (2004) *Microbiol Mol Biol Rev* 68, 320-44.
- (2) Baccarini, M. (2005) FEBS Lett 579, 3271-7.
- (3) Meloche, S. and Pouysségur, J. (2007) *Oncogene* 26, 3227-39.
- (4) Roberts, P.J. and Der, C.J. (2007) *Oncogene* 26, 3291-310.
- (5) Rubinfeld, H. and Seger, R. (2005) *Mol Biotechnol* 31, 151-74.
- (6) Murphy, L.O. and Blenis, J. (2006) *Trends Biochem Sci* 31, 268-75.
- (7) Dalby, K.N. et al. (1998) J Biol Chem 273, 1496-505.
- (8) Marais, R. et al. (1993) Cell 73, 381-93.
- (9) Kortenjann, M. et al. (1994) Mol Cell Biol 14, 4815-24.
- (10) Owens, D.M. and Keyse, S.M. (2007) *Oncogene* 26, 3203-13.





Orders	877-616-CELL (2355)
	orders@cellsignal.com
Support	877-678-TECH (8324)
	info@cellsignal.com
Web	www.cellsignal.com

### Entrez-Gene ID # 5595, 5594 Swiss-Prot Acc. # P27361, P28482

#### Storage: Store at 4° C.

Optimal staining is achieved if slides are stained following CST's standard IHC protocols and are used within 8 weeks of assay date; however, signals may persist beyond two months.

For application specific protocols please see the web page for this product at www.cellsignal.com.

Please visit www.cellsignal.com for a complete listing of recommended companion products.

Applications Key: W—Western IP—Immunoprecipitation IHC—Immunohistochemistry ChIP—Chromatin Immunoprecipitation IF—Immunofluorescence F—Flow cytometry E-P—ELISA-Peptide Species Cross-Reactivity Key: H—human M—mouse R—rat Hm—hamster Mk—monkey Mi—mink C—chicken Dm—D. melanogaster X—Xenopus Z—zebrafish B—bovine Dq—dog Pq—pig Sc—S. cerevisiae Ce—C. elegans Hr—Horse AII—all species expected Species enclosed in parentheses are predicted to react based on 100% homology.